The Top 5 Biosimilars Articles for the Week of September 10

The Center for Biosimilars® recaps the top news for the week of September 10, 2018.
September 14, 2018


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of September 10.

Number 5: While biosimilar filgrastim and biosimilar pegfilgrastim are effective in reducing the incidence of neutropenia, adverse events were shown in a recent study to be higher in patients who receive pegfilgrastim.

Number 4: Xbrane Biopharma has announced its intention to shift its focus from generic drugs to biosimilars. 
Number 3: Newly published study results show that switching to Retacrit was noninferior to continuing treatment with Epogen. 

Number 2: The United Kingdom is hoping to bring more biosimilar developers’ phase 3 trials to the nation’s National Health Service.

Number 1: The FDA’s Oncologic Drugs Advisory Committee will meet next month to discuss Celltrion’s rituximab biosimilar. 

Finally, last week, our e-newsletter asked whether you think that biosimilar should be approved without the need for phase 3 studies.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit 



Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.